Orion Oyj Full Year 2024 Earnings: EPS Beats Expectations

Orion Oyj (HEL:ORNBV) Full Year 2024 Results

Key Financial Results

• Revenue: €1.54b (up 30% from FY 2023).
• Net income: €329.9m (up 52% from FY 2023).
• Profit margin: 21% (up from 18% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: €2.35 (up from €1.55 in FY 2023).

ORNBV Products In Clinical Trials

• Phase I: 1.
• Phase II: 2.
• Phase III: 3.

ORNBV Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Orion Oyj EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%.

Looking ahead, revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Finland.

The company's shares are up 4.3% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Orion Oyj, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.